Loading...
•
Dec 31, 2024
4DMT Q4 2024 Earnings Report
4D Molecular Therapeutics reported its full year 2024 financial results, operational highlights, and expected upcoming milestones.
Key Takeaways
4D Molecular Therapeutics reported a net loss of $160.9 million for the full year 2024, an increase from $100.8 million in 2023. Research and development expenses significantly increased to $141.3 million, driven by the progression of clinical trials. The company ended 2024 with $505 million in cash, cash equivalents, and marketable securities, extending its cash runway into 2028.
Positive interim data for 4D-150 in wet AMD and DME were reported, showing robust clinical activity and favorable tolerability.
The 4FRONT Phase 3 program for wet AMD is on track, with initiations expected in March and Q3 2025, and topline data in 2H 2027.
The company strategically focused its pipeline on core programs (4D-150 for wet AMD/DME and 4D-710 for cystic fibrosis) to optimize resource allocation.
Cash, cash equivalents, and marketable securities totaled $505 million as of December 31, 2024, expected to fund operations into 2028.
4DMT
4DMT
4DMT Revenue by Segment
Revenue by Segment
Collaboration & license rev. Revenue
CapyFin.com Forward Guidance
4D Molecular Therapeutics expects to initiate Phase 3 clinical trials for 4D-150 in wet AMD in March and Q3 2025, with topline data anticipated in H2 2027. The company's cash position is projected to fund operations into 2028.
Positive Outlook
- 4FRONT-1 and 4FRONT-2 Phase 3 clinical trials for wet AMD expected to initiate in March and Q3 2025, respectively.
- Primary endpoint 52-week topline data from both 4FRONT-1 and 4FRONT-2 expected in H2 2027.
- 52-week interim data update from Part 1 of SPECTRA for 4D-150 in DME expected at a scientific conference in Q3 2025.
- Interim data and program update from AEROW clinical trial for 4D-710 in CF Lung Disease expected at a scientific conference in H2 2025.
- Cash, cash equivalents and marketable securities of $505 million expected to fund planned operations into 2028.
Challenges Ahead
- No specific negative forward guidance was provided in the report.
- No specific negative forward guidance was provided in the report.
- No specific negative forward guidance was provided in the report.
- No specific negative forward guidance was provided in the report.
- No specific negative forward guidance was provided in the report.